High throughput sequencing analysis of intestinal microbiome in hemodialysis patients with type 2 diabetes

doi:10.3877/cma.j.issn.2095-3216.2024.06.003

Abstract

Abstract:

Objective

To explore the characteristics and changes of intestinal microbiome in hemodialysis patients with type 2 diabetes mellitus based on RNA sequencing technology.

Methods

This cross-sectional study enrolled hemodialysis patients who visited the Chinese PLA General Hospital from May to December 2023. The hemodialysis patients with type 2 diabetes were divided into a type 2 diabetes group，while those matched at the same time without type 2 diabetes were divided as a control group. General information and clinical data were collected from all the enrolled patients. Fecal samples from the patients were analyzed for their microbial composition by means of high-throughput RNA sequencing techniques，exploring the differences in α diversity， β diversity， and species of intestinal microbiota between the two groups.

Results

A total of 52 hemodialysis patients were included，with 26 in the type 2 diabetes group and 26 in the control group. There was a statistically significant difference in the β diversity of intestinal microbiota between the two groups （P ＜0. 05）， but not in the α diversity （P ＞0. 05）. There were significant differences between the two groups in a total of 11 intestinal microbiota （linear discriminant analysis threshold 4， P ＜0.05）. The type 2 diabetes group significantly enriched Proteobacteria， Gamma Proteobacteria， Enterobacteriaceae， Christenseniaceae， Enterobacteriaceae， and its Escherichia， while the control group significantly enriched Firmicutes， Clostridia， Eubacilli， Trichospiriceae， and its Brautzia.

Key words: Hemodialysis, Type 2 diabetes, Intestinal microbiome

Junxia Du, Xiaolin Zhao, Haoran Wang, Zhiyuan Gao, Manqian Wang, Nanxi Wan, Dong Zhang, Xiaonan Ding, Qinqin Ren, Yingjie Duan, Li Tang, Hanyu Zhu. High throughput sequencing analysis of intestinal microbiome in hemodialysis patients with type 2 diabetes[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 313-320.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2024.06.003

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2024/V13/I06/313

Figures/Tables 5

References 40

［1］	Nordio M， Limido A， Maggiore U， et al. Survival in patients treated by long-term dialysis compared with the general population ［J］. Am J Kidney Dis，2012，59（6）：819-828.
［2］	Murdeshwar HN， Anjum F. Hemodialysis［M］. Treasure Island（FL）： StatPearls，2024.
［3］	Ley RE， Peterson DA， Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine ［J］.Cell，2006，124（4）：837-848.
［4］	Xu J， Gordon JI. Honor thy symbionts ［J］. Proc Natl Acad Sci USA，2003，100（18）：10452-10459.
［5］	Huang JK， Wu PH， Chen ZF， et al. Identification of gut microbiome signatures associated with indole pathway in tryptophan metabolism in patients undergoing hemodialysis ［J］.Biomolecules，2024，14（6）：623.
［6］	Gurung M， Li Z， You H， et al. Role of gut microbiota in type 2 diabetes pathophysiology ［ J］. EBioMedicine， 2020， 51：102590.
［7］	Zhao L， Zhang F， Ding X， et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes ［ J］.Science，2018，359（6380）：1151-1156.
［8］	Estrada V， Gonzalez N. Gut microbiota in diabetes and HIV：inflammation is the link ［J］. EBioMedicine，2018，38：17-18.
［9］	Flynn MC，Kraakman MJ，Tikellis C，et al. Transient intermittent hyperglycemiaacceleratesatherosclerosisbypromoting myelopoiesis ［J］. Circ Res，2020，127（7）：877-892.
［10］	Trandafir MF， Savu OI， Gheorghiu M. The complex immunological alterations in patients with type 2 diabetes mellitus on hemodialysis ［J］. J Clin Med，2024，13（13）：3687.
［11］	Wang Y， Gao L. Inflammation and cardiovascular disease associated with hemodialysis for end-stage renal disease ［J］.Front Pharmacol，2022，13：800950.
［12］	中国老年2 型糖尿病防治临床指南编写组，中国老年医学学会老年内分泌代谢分会，中国老年保健医学研究会老年内分泌与代谢分会，等. 中国老年2 型糖尿病防治临床指南（2022 年版）［J］. 中华内科杂志，2022，61（1）：12-50.
［13］	Gao Y， Zhang G， Jiang S， et al. Wekemo Bioincloud： a userfriendly platform for meta-omics data analyses ［J］. Imeta，2024，3（1）： e175.
［14］	Larsen N， Vogensen FK， Van Den Berg FW， et al. Gut microbiota in human adults with type 2 diabetes differs from nondiabetic adults ［J］. PLoS One，2010，5（2）： e9085.
［15］	Zhao L， Lou H， Peng Y， et al. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications ［J］. Endocrine，2019，66（3）：526-537.
［16］	Du Y， Neng Q， Li Y， et al. Gastrointestinal autonomic neuropathy exacerbates gut microbiota dysbiosis in adult patients with type 2 diabetes mellitus ［J］. Front Cell Infect Microbiol，2021，11：804733.
［17］	Allcock GH， Allegra M， Flower RJ， et al. Neutrophil accumulation induced by bacterial lipopolysaccharide： effects of dexamethasone and annexin 1 ［J］. Clin Exp Immunol， 2001，123（1）：62-67.
［18］	Amar J， Chabo C， Waget A， et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes： molecular mechanisms and probiotic treatment ［J］.EMBO Mol Med，2011，3（9）：559-572.
［19］	Hays KE， Pfaffinger JM， Ryznar R. The interplay between gut microbiota， short-chain fatty acids， and implications for host health and disease［J］. Gut Microbes，2024，16（1）：2393270.
［20］	Furusawa Y， Obata Y， Fukuda S， et al. Commensal microbederived butyrate induces the differentiation of colonic regulatory T cells ［J］. Nature，2013，504（7480）：446-450.
［21］	Du L， Li Q， Yi H， et al. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus ［ J ］. Biomed Pharmacother，2022，149：112839.
［22］	Ignatyeva O， Tolyneva D， Kovalyov A， et al. Christensenella minuta， a new candidate next-generation probiotic： current evidence and future trajectories［J］. Front Microbiol，2024，14：1241259.
［23］	Peters BA， Shapiro JA， Church TR， et al. A taxonomic signature of obesity in a large study of American adults ［J］. Sci Rep，2018，8（1）：9749.
［24］	Org E， Blum Y， Kasela S， et al. Relationships between gut microbiota， plasma metabolites， and metabolic syndrome traits in the METSIM cohort ［J］. Genome Biol，2017，18（1）：70.
［25］	Waters JL， Ley RE. The human gut bacteria Christensenellaceae are widespread， heritable， and associated with health ［J］. BMC Biol，2019，17（1）：83.
［26］	Alemán JO， Bokulich NA， Swann JR， et al. Fecal microbiota and bile acid interactions with systemic and adipose tissue metabolism in diet-induced weight loss of obese postmenopausal women ［J］. J Transl Med，2018，16（1）：244.
［27］	Xu R，Tan C，Zhu J，et al. Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death ［J］. Crit Care，2019，23（1）：195.
［28］	Shen T， Yue Y， He T， et al. The association between the gut microbiota and Parkinson′s disease， a meta-analysis ［J］. Front Aging Neurosci，2021，13：636545.
［29］	Verhaar BJH， Hendriksen HMA， De Leeuw FA， et al. Gut microbiota composition is related to AD pathology ［J］. Front Immunol，2021，12：794519.
［30］	Galluzzo P， Capri FC， Vecchioni L， et al. Comparison of the intestinal microbiome of Italian patients with multiple sclerosis and their household relatives ［J］. Life （Basel），2021，11（7）：620.
［31］	Prochazkova P， Roubalova R， Dvorak J， et al. The intestinal microbiota and metabolites in patients with anorexia nervosa ［J］.Gut Microbes，2021，13（1）：1-25.
［32］	Palacios T， Vitetta L， Coulson S， et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia： a randomised controlled pilot study［J］. Nutrients，2020，12（7）：2041.
［33］	Shen X， Ma C， Yang Y， et al. The role and mechanism of probiotics supplementation in blood glucose regulation： a review［J］. Foods，2024，13（17）：2719.
［34］	Wang CH， Yen HR， Lu WL， et al. Adjuvant probiotics of Lactobacillus salivarius subsp. salicinius AP-32， L. johnsonii MH-68， and Bifidobacterium animalis subsp. Lactis CP-9 attenuate glycemic levels and inflammatory cytokines in patients with type 1 diabetes mellitus ［ J ］. Front Endocrinol（Lausanne），2022，13：754401.
［35］	Eidi F， Poor-Reza Gholi F， Ostadrahimi A， et al. Effect of Lactobacillus Rhamnosus on serum uremic toxins （phenol and pcresol） in hemodialysis patients： a double blind randomized clinical trial ［J］. Clin Nutr ESPEN，2018，28：158-164.
［36］	Natarajan R， Pechenyak B， Vyas U， et al. Randomized controlled trial of strain-specific probiotic formulation （Renadyl）in dialysis patients ［J］. Biomed Res Int，2014，2014：568571.
［37］	Choi E， Yang J， Ji GE， et al. The effect of probiotic supplementation on systemic inflammation in dialysis patients［J］. Kidney Res Clin Pract，2022，41（1）：89-101.
［38］	Soleimani A， Zarrati Mojarrad M， Bahmani F， et al. Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects ［J］. Kidney Int，2017，91（2）：435-442.
［39］	Wang S， Li D， Li G， et al. Functional properties， rheological characteristics， simulated digestion， and fermentation by human fecal microbiota of polysaccharide from morchella importuna ［J］.Foods，2024，13（13）：2148.
［40］	魏慧，段丽萍. 膳食对肠道菌群结构、代谢和功能影响的研究进展［J］. 中华消化杂志，2017，37（9）：642-644.

项目	对照组（26例）	2型糖尿病组（26例）	P值
年龄（岁）	61.5（51.0～67.3）	61.5（51.0～67.3）	0.991
男性［例（%）］	13（50.0）	13（50.0）	1.000
身体质量指数（kg/m²）	21.13±2.12	21.74±2.94	0.393
动静脉内瘘［例（%）］	21（80.8）	19（73.1）	0.510
透析周期（月）	49.0（34.8～99.0）	53.5（20.0～91.3）	0.487
白蛋白（g/L）	39.20（36.90～41.40）	40.20（36.70～42.25）	0.735
肌酐（μmol/L）	859.20（753.90～1142.78）	862.35（578.53～1013.50）	0.600
尿素（mmol/L）	25.86±1.29	24.66±1.16	0.159
尿酸（μmol/L）	401.30±18.75	406.93±16.03	0.872
空腹血糖（mmol/L）	5.99（5.06～7.61）	9.83（6.28～11.13）	0.003
甘油三脂（mmol/L）	2.51（1.33～3.29）	2.99（1.56～3.87）	0.510
总胆固醇（mmol/L）	3.21（1.17～4.37）	2.96（1.36～4.68）	0.978
高密度脂蛋白胆固醇（mmol/L）	1.13±0.05	1.13±0.07	0.349
低密度脂蛋白胆固醇（mmol/L）	2.23±0.17	2.21±0.18	0.672
血红蛋白（g/L）	107.00（95.75～126.25）	115.50（104.75-121.50）	0.272
超敏C反应蛋白（mg/dl）	0.85（0.34～2.17）	0.37（0.32～0.98）	0.184

项目	对照组（26例）	2型糖尿病组（26例）	P值
年龄（岁）	61.5（51.0～67.3）	61.5（51.0～67.3）	0.991
男性［例（%）］	13（50.0）	13（50.0）	1.000
身体质量指数（kg/m²）	21.13±2.12	21.74±2.94	0.393
动静脉内瘘［例（%）］	21（80.8）	19（73.1）	0.510
透析周期（月）	49.0（34.8～99.0）	53.5（20.0～91.3）	0.487
白蛋白（g/L）	39.20（36.90～41.40）	40.20（36.70～42.25）	0.735
肌酐（μmol/L）	859.20（753.90～1142.78）	862.35（578.53～1013.50）	0.600
尿素（mmol/L）	25.86±1.29	24.66±1.16	0.159
尿酸（μmol/L）	401.30±18.75	406.93±16.03	0.872
空腹血糖（mmol/L）	5.99（5.06～7.61）	9.83（6.28～11.13）	0.003
甘油三脂（mmol/L）	2.51（1.33～3.29）	2.99（1.56～3.87）	0.510
总胆固醇（mmol/L）	3.21（1.17～4.37）	2.96（1.36～4.68）	0.978
高密度脂蛋白胆固醇（mmol/L）	1.13±0.05	1.13±0.07	0.349
低密度脂蛋白胆固醇（mmol/L）	2.23±0.17	2.21±0.18	0.672
血红蛋白（g/L）	107.00（95.75～126.25）	115.50（104.75-121.50）	0.272
超敏C反应蛋白（mg/dl）	0.85（0.34～2.17）	0.37（0.32～0.98）	0.184

[1]	Wenjia Cao, Xuebing Liu, Anguo Luo, Shimin Zhong, Lan Deng, Yulin Wang, Zhaohuan Li. Evaluation of wall shear stress of the carotid artery by ultrasound vector flow imaging in patients with type 2 diabetes mellitus [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(07): 709-717.
[2]	Haoyuan Wang, Shu Wang, Juan Wang, Jianjun Yang. Research progress on the relationship between intestinal tract and gut microbiota based on organoid model [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(03): 220-224.
[3]	Lingkai Meng, Dayong Li, Ning Wang, Guiming Wang, Bingnan Zhang, Ruotong Li, Lifeng Pan. Effect and mechanism of sleeve gastrectomy on obese rats with type 2 diabetes mellitus [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 638-642.
[4]	Meng Li, La Jiang, Lei Dong, Qing Wu, Ben Li Jia. Clinical study of laparoscopic gastric sleeve resection in the treatment of obesity complicated with type 2 diabetes mellitus and fatty pancreas [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 554-557.
[5]	Hongxia Yan, Xiaojuan Wang, Yixun Zhang. The effect of type 2 diabetes on tumor markers， clinicopathology and prognosis in patients with colorectal cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 483-487.
[6]	Shaoqing Zhang, Yufeng Lv, Haixia Dong. The predictive effect of neutrophil percentage-to-albumin ratio for all-cause mortality in maintenance hemodialysis patients [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 321-326.
[7]	Chaojiang Su, Jiali Liu, Yan Jiang, Ting Xu, Liting Liu, Yan Chen, Zongyang Liu. Effect of percutaneous transluminal angioplasty prior to arteriovenous fistula creation for small-diameter artery in hemodialysis patients [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 249-255.
[8]	Min Zhou, Yang Xu, Ying Hu, Xianfeng Huang. Relationship of serum β-CTX，N-MID，and PICP with coronary artery calcification in maintenance hemodialysis patients and its diagnostic value [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(05): 256-260.
[9]	Wenqi Lu, Yanru Zhao, Huandi Li, Xinna Fan, Jia Wang, Ping Li. Serum expression of SMAD2 and SOX6 in patients with type 2 diabetes mellitus and their relationship with proteinuria [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 145-151.
[10]	Xuan Wang, ·Nijiati Nazhakaiti, Yangyang Luo, Sheng Jiang. Correlation between skin levels of advanced glycation end products and risk of microvascular complications in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 447-454.
[11]	Xing Wang, Yuan Chen, , Wusman Rezi Wan Guli, Yanying Guo. Co-pathogenic genes and potential common molecular mechanisms of type 2 diabetes mellitus, obesity, nonalcoholic steatohepatitis, and polycystic ovary syndrome [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 481-490.
[12]	Xiuqin Sun, Meijuan Gao, Qiongge Zhang, Kaimin Lv, Hongyu Wang. Cardiovascular risk factors in middle-aged and elderly people with type 2 diabetes without cardiovascular history in western Beijing [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(03): 245-252.
[13]	Xiaoming Wu, Yangkui Zhai, Juan Wang, Shuo Zhang, Jie Xu, Congqing Pan. Association of fasting c-peptide and quantitative insulin sensitivity index with arteriosclerosis index of plasma in male patients with T2DM [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(04): 288-294.
[14]	Mei Zhang, Hui Chen, Zhuanxia Li, Rui Wang, Linjuan Li. Metrnl and NLRP3 Inflammasome: Potential diagnostic biomarkers for diabetic kidney disease [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(03): 193-199.
[15]	Zilong Wu, Bing Wu, Kaisheng Yuan, Ruixiang Hu, Wah Yang, Cunchuan Wang. Research progress of obesity and pancreatic diseases [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2024, 10(03): 213-219.

Please choose a citation manager

Content to export